This review concluded that oestrogen-based hormone therapy had a beneficial effect on muscle strength in postmenopausal women. However, given the pooling of studies with quite different study designs and characteristics, and the risk of missing studies, the findings may not be reliable.
Study selection
Studies that compared muscle strength (maximal force, torque or power generated by a group of muscles) in postmenopausal women who were and were not receiving oestrogen-based hormone therapy were eligible for inclusion in the review. Methods used to assess muscle strength had to be clearly described, as did participant ages and study inclusion/exclusion criteria. Studies that presented outcome data as adjusted means were excluded. Studies on the effects of oestrogen on muscle strength in rodents were also included in the review, but these data were not reported in this summary.
Most included studies assessed women who took different oestrogen-based therapies. The most frequently used dose, where stated, was 0.6mg of oestrogen per day (range 0.4mg to 4.3mg per day). Therapies were used for a mean of 110 months. Mean age of participants ranged from 51 to 77 years. Mean time since menopause ranged from 0.5 to 30 years. All of the reported cross-sectional studies included women who had previously used hormone therapies; most of the longitudinal studies excluded participants who had previously used hormone therapies.
Two reviewers independently assessed studies for inclusion in the review.
Assessment of study quality
Study quality was assessed independently by two authors using the Physiotherapy Evidence-based Database (PEDro) Scale (individual criteria were not reported). Each study was awarded a score up to a maximum of 11 points
Data extraction
One author extracted data and a second author checked the data for accuracy. For randomised controlled trials (RCTs), mean changes in muscle strength (and standard deviation) from baseline to follow-up were extracted. Where mean values were not available, percentage changes and p values were extracted. Authors were contacted where necessary to try and obtain data for strength normalised to muscle cross-sectional area. Standardised mean differences were calculated for cross-sectional studies from percentage differences and p values (a correlation of 0.8 was used). Where studies assessed outcomes at different time points, data were averaged across the time points and similarly data were averaged across different muscle groups.
Methods of synthesis
Pooled effect sizes with 95% confidence intervals were calculated using a random-effects model. Further analyses were carried out to investigate the effects of oestrogen in different subgroups dependent on previous hormone therapy use, study design (RCT and non-RCT), type of muscle group (thumb abductors, forearm flexors, hip abductors, knee extensors and knee flexors) and type of muscle contraction (isometric and isokinetic). The effects of participants' time
